Raymond James & Associates Foghorn Therapeutics Inc. Call Options Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FHTX
# of Institutions
70Shares Held
23.6MCall Options Held
7.7KPut Options Held
1.4K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$60.8 Million5.6% of portfolio
-
Euclidean Capital LLC New York, NY1.57MShares$7.55 Million1.36% of portfolio
-
Black Rock Inc. New York, NY1.32MShares$6.31 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.1MShares$5.29 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N4721KShares$3.46 Million0.26% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $200M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...